If you loved our Explainer on Antimicrobial Resistance, you'll love this new summarised version. This short report takes you through the key BIA member companies working in the AMR space, and explains the cutting-edge work taking place in the UK.
PrecisionLife has launched Biology Matters, a new podcast exploring how advances in biology, genomics, data science, and AI can help address one of healthcare's greatest challenges: chronic disease.
Poolbeg Pharma has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (CRS) patent application.
Explore Columbus Global's latest life science report featuring expert into the digital trends shaping the future of Pharma, MedTech and Biotech in 2026 and beyond.
Poolbeg Pharma announces new research on two posters, by Poolbeg and The University of Manchester respectively, are being presented at the European Hematology Association Congress.
Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred.
